ERBB2 and breast cancer: In contrast, the role of TILs in ER+HER2- breast cancers remains elusive [52] and may identify tumors exhibiting unfavorable clinicopathological factors, such as high tumor grade, more advanced stage, and younger age, resulting in poorer clinical outcomes.